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ABSTRACT Daily oral tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) is a
safe and effective intervention for HIV preexposure prophylaxis (PrEP). We evalu-
ated the performance of a qualitative assay that detects 20 antiretroviral (ARV)
drugs (multidrug assay) in assessing recent PrEP exposure (detection limit, 2 to 20
ng/ml). Samples were obtained from 216 Black men who have sex with men (208
HIV-uninfected men and 8 seroconverters) who were enrolled in a study in the
United States evaluating the acceptability of TDF-FTC PrEP (165 of the uninfected
men and 5 of the seroconverters accepted PrEP). Samples from 163 of the 165 HIV-
uninfected men who accepted PrEP and samples from all 8 seroconverters were also
tested for tenofovir (TFV) and FTC using a quantitative assay (detection limit for
both drugs, 0.31 ng/ml). HIV drug resistance was assessed in seroconverter samples.
The multidrug assay detected TFV and/or FTC in 3 (1.4%) of the 208 uninfected men
at enrollment, 84 (40.4%) of the 208 uninfected men at the last study visit, and 1
(12.5%) of the 8 seroconverters. No other ARV drugs were detected. The quantitative
assay confirmed all positive results from the multidrug assay and detected TFV
and/or FTC in 9 additional samples (TFV range, 0.65 to 16.5 ng/ml; FTC range, 0.33
to 14.6 ng/ml). Resistance mutations were detected in 4 of the 8 seroconverter sam-
ples. The multidrug assay had 100% sensitivity and specificity for detecting TFV and
FTC at drug concentrations consistent with daily PrEP use. The quantitative assay de-
tected TFV and FTC at lower levels, which also might have provided protection
against HIV infection.
KEYWORDS antiretroviral drug, HIV, HPTN 073, preexposure prophylaxis, Truvada,
adherence
Daily preexposure prophylaxis (PrEP) with a combination of tenofovir disoproxilfumarate (TDF) and emtricitabine (FTC) is a safe and effective intervention for
preventing HIV infection (1, 2). The efficacy of this regimen has been demonstrated in
different risk groups, including men who have sex with men (MSM), transgender and
cisgender women, serodiscordant couples, and persons who inject drugs (1, 3–7). In
2012, the U.S. Food and Drug Administration (FDA) approved daily oral use of TDF-FTC
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for PrEP (8). TDF-FTC PrEP is now recommended by the U.S. Centers for Disease Control
and Prevention and the World Health Organization for prevention of HIV infection (9,
10). A nondaily regimen that includes TDF-FTC dosing before and after sex events has
also been shown to be effective for preventing HIV infection in MSM (11). The efficacy
of TDF-FTC PrEP regimens is strongly associated with adherence (1, 2).
Antiretroviral (ARV) drug testing provides an objective biomedical measure of ARV
drug use (12). ARV drug testing for evaluation of adherence to TDF-FTC regimens is
often performed using quantitative assays based on liquid chromatography-tandem
mass spectrometry (LC-MS/MS) (13–17). Steady-state concentrations of tenofovir (TFV)
in plasma are achieved after a few days of daily oral dosing. In a placebo-controlled
PrEP efficacy trial, plasma TFV concentrations of40 ng/ml were shown to provide 91%
risk reduction for individuals receiving daily TDF-FTC (16). HIV Prevention Trials Network
[HPTN] 066 was a 5-week, directly observed TDF-FTC dosing study (13); the study
included a daily dosing regimen and a 4-dose/week regimen. The 90% sensitivity
thresholds for serum TFV and FTC concentrations in HPTN 066 were 35.5 and 49.1
ng/ml, respectively, for daily dosing and 4.2 and 4.6 ng/ml, respectively, for the
4-dose/week regimen (13). We previously developed a qualitative method based on
high-resolution mass spectrometry (HRMS) (18) that is less costly than LC-MS/MS
methods. That assay detected 15 or 16 ARV drugs in three drug classes (19–21). The
multidrug assay was recently modified to detect 20 ARV drugs in five drug classes (22).
In this report, we validated the new version of the multidrug assay for ARV drug
detection and determined its performance characteristics. We then evaluated the
performance of the assay for monitoring PrEP exposure in a cohort of Black MSM
enrolled in a clinical study evaluating PrEP uptake and adherence at three sites in the
United States (Washington, DC; Los Angeles, California; and Chapel Hill, North Carolina),
the HPTN 073 study (2013 to 2015) (23). Because the multidrug assay detects most ARV
drugs currently in use, we were also able to assess the use of other ARV drugs among
HIV-uninfected men and seroconverters in the HPTN 073 cohort.
RESULTS
Validation of the multidrug assay. Validation studies were performed to deter-
mine the performance characteristics of the multidrug assay. As a first step, we tested
the ability of the assay to detect ARV drugs at the limit of detection (LOD) of the assay
by injecting five replicates of an LOD control twice a day for 10 days. More than 95%
of the samples spiked with compounds at the LOD were identified over the course of
the experimental period. Carryover studies indicated that no carryover was present
for any of the ARV drugs in blank injections following an injection of the same drug
at a concentration of 2,000 ng/ml. Some carryover was detected at concentrations of
5,000 and 10,000 ng/ml. Therefore, a 2,000 ng/ml control was added to each plate. If
any test sample had a signal above this control level for any ARV drug in the assay and
the subsequent sample was positive for the same ARV drug, then the second sample
was flagged for reinjection. The multidrug assay was further validated for detection of
ARV drugs by performing an external method comparison study with 25 blinded
samples (provided by the Johns Hopkins Clinical Pharmacology Analytical Laboratory)
that had been analyzed previously using the gold standard, a quantitative LC-MS/MS
assay. These samples contained 16 of the 20 drugs included in the current version of
the multidrug assay (tipranavir, nelfinavir, darunavir, and zidovudine were not present
in the blinded sample set). The multidrug assay correctly identified 98% of ARV drugs
present in the blinded sample set (see Table S1 in the supplemental material). The
sensitivity and specificity of the multidrug assay in this analysis were 98.7% and 100%,
respectively. To supplement this analysis, an internal blinded spiking experiment was
performed using 20 samples that contained the four ARV drugs not present in the
previous validation sample set. These four drugs were present in the validation samples
at various concentrations, and the validation samples were also spiked with TFV and
FTC prior to testing. These samples were prepared in a different laboratory by a
technologist who was not involved in sample analysis. In this set of samples, the
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multidrug assay detected all of the spiked compounds (100% agreement). Finally, 40
additional samples from ARV-naïve individuals were analyzed; no ARV drugs were
detected in those samples.
Analysis of ARV drug use in HIV-uninfected men enrolled in HPTN 073. We
further evaluated the performance of the multidrug assay by testing plasma samples
collected in the HPTN 073 study (Fig. 1). Paired plasma samples collected from HIV-
uninfected men at study enrollment and at the end-of-study visit were available for
208/226 (92%) of the men enrolled in the study. The 208 men included 43 men who did
not accept PrEP and 165 men who accepted PrEP; 29 (17.6%) of the 165 men who
accepted PrEP permanently discontinued PrEP during the study and 136 did not. The
median time between study enrollment and collection of the end-of-study sample for
the 208 men was 52 weeks (range, 4 to 89 weeks). The only ARV drugs detected using
the multidrug assay were TFV and FTC. The multidrug assay detected TFV and/or FTC
in 3 (1.4%) of the 208 enrollment samples and 84 (40.4%) of the 208 end-of-study
samples (Table 1). All 3 of the enrollment samples and 81 (96.4%) of the 84 end-of-study
samples in which drugs were detected were from men who accepted PrEP; 3 (3.7%) of
the 81 men who accepted PrEP and had drugs detected at their last study visit reported
that they had permanently discontinued PrEP before their last visit. TFV and FTC were
not detected in any of the enrollment samples from the 43 men who did not accept
PrEP, but they were detected in 3 (7.0%) of the end-of-study samples from those men.
Comparison of TFV and FTC detection using the multidrug assay and a quan-
titative TFV-FTC assay. The performance of the multidrug assay in detecting TFV and
FTC was further evaluated by comparing results from the multidrug assay with results
obtained for these two drugs using a more sensitive quantitative TFV-FTC assay. The
latter assay was used in the HPTN 066 study, which determined the concentrations of
TFV and FTC achieved during 5 weeks of directly observed TDF-FTC dosing with a daily
FIG 1 Flow chart of laboratory testing. All samples from 208 uninfected participants and 8 seroconverters were tested for
the presence of ARV drugs using the qualitative multidrug assay; this assay detects 20 ARV drugs based on HRMS. The
lower limit of detection was 2 to 20 ng/ml. A subset of follow-up samples from uninfected participants who accepted PrEP
were tested using a quantitative assay for TFV and FTC that was based on LC-MS/MS. The lower limit of quantification was
0.31 ng/ml for both drugs. HIV drug resistance was assessed using the ViroSeq HIV-1 genotyping system and next-
generation sequencing. The asterisk in the figure indicates that all 165 follow-up samples from uninfected PrEP acceptors
were tested with the multidrug assay but two of the samples were not tested with the quantitative TFV-FTC assay due to
insufficient sample volume.
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dosing regimen and a 4-dose/week regimen (13). That benchmark study found that the
90% sensitivity thresholds for TFV and FTC were 35.5 ng/ml and 49.1 ng/ml, respec-
tively, for the daily dosing regimen and 4.2 and 4.6 ng/ml, respectively, for the
4-dose/week regimen (13). Results from the quantitative TFV-FTC assay were available
for 163 of 165 HIV-uninfected men who accepted PrEP (end-of-study visits only; two
participants did not have samples available for testing). The quantitative TFV-FTC assay
detected TFV in 85 (52.1%) of the 163 samples (median concentration, 87.5 ng/ml
[range, 0.7 to 424.0 ng/ml]) (Table 2) and detected FTC in 87 (53.4%) of the 163 samples
(median concentration, 342.0 ng/ml [range, 0.3 to 3,230.0 ng/ml]) (Table 2). Most men
for whom TFV and/or FTC was detected had drug concentrations consistent with daily
TDF-FTC use; 70 (42.9%) had TFV concentrations above 35.5 ng/ml and 73 (44.8%) had
FTC concentrations above 49.1 ng/ml. The multidrug assay detected TFV and FTC only
in samples in which the drugs were detected using the quantitative TFV-FTC assay, and
it detected the drugs in all cases in which those drugs were present at concentrations
above 20 ng/ml. In nine cases, TFV and/or FTC were detected only using the quanti-
tative TFV-FTC assay; in all nine cases, the drugs were present at concentrations below
20 ng/ml (TFV range, 0.65 to 16.50 ng/ml; FTC range, 0.33 to 14.60 ng/ml) (see Table S2).
Using the quantitative TFV-FTC assay as the gold standard, the sensitivity of the
multidrug assay for this sample set was 91.8% for TFV and 92.0% for FTC; the accuracy
was 95.7% and the specificity was 100% for both drugs.
Analysis of ARV drug use and drug resistance among men in HPTN 073 who
acquired HIV infection. As a final step, we analyzed ARV drug use and HIV drug
resistance among the eight men who acquired HIV infection during the HPTN 073
study; this included five men who accepted PrEP and three who did not (Fig. 2). The
only drugs detected in samples from these men were TFV and FTC. In the three cases
in which men did not accept PrEP (cases A to C), TFV and FTC were not detected in any
samples using either the multidrug assay or the quantitative TFV-FTC assay (Fig. 2). In
three of the five cases in which men accepted PrEP (cases D, E, and F), TFV or FTC was
TABLE 1 Antiretroviral drugs detected using the multidrug assay
ARV drugs
detected
No. of samplesa
Total
(n  416)
Enrollment visit (n  208) Last visit (n  208)
Did not
accept PrEP
Accepted
PrEP
Did not
accept PrEP
Accepted
PrEP
FTC 3 0 0 1 2
TFV 1 0 1 0 0
TFV and FTC 83 0 2 2 79
None 329 43 162 40 84
aPlasma samples were collected at the enrollment visit and the end-of-study visit from 208 participants in
HPTN 073, including 165 who accepted PrEP and 43 who did not accept PrEP. Twenty-nine of the 165 men
who accepted PrEP permanently discontinued PrEP before their last study visit. Samples were tested for the
presence of 20 ARV drugs using the multidrug assay, and TFV and FTC were the only drugs detected in the
samples.
TABLE 2 Detection of TFV and FTC using the multidrug assay and the quantitative TFV/
FTC assaya
Multidrug
assay result
TFV FTC
Quantitative
assay positive
Quantitative
assay negative Total
Quantitative
assay positive
Quantitative
assay negative Total
Positive 78 0 78 80 0 80
Negative 7 78 85 7 76 83
Total 85 76 163 87 78 163
aPlasma samples from HPTN 073 were tested using the multidrug assay and the quantitative TFV-FTC assay.
The number of samples in which TFV or FTC was detected with one or both test methods is shown.
Positive indicates that TFV or FTC was detected, and negative indicates that the corresponding drug was
not detected. Both drugs were detected in 85 (52.1%) of the 163 samples.
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FIG 2 ARV drug use among men who acquired HIV infection (cases A to H). Plasma samples were obtained from eight men who acquired HIV infection during
the HPTN 073 study. The arrows with negative signs indicate the last study visit at which the participants tested negative for HIV infection, and the arrows with
positive signs indicate the first visit at which the participants tested positive for HIV infection. The solid lines indicate the time period before the diagnosis of
HIV infection. The number of weeks after the enrollment visit is shown. Samples were tested using the qualitative multidrug assay (assay cutoff value, 2 to 20
ng/ml) and the quantitative TFV-FTC assay (lower limit of quantification, 0.31 ng/ml for both drugs). Hatched bars indicate the periods during which the
participants had access to PrEP in the study. Self-reports included the percentage of TDF-FTC pills taken over the prior month (data are noted only for visits
at which the participant reported taking PrEP). Participants who accepted PrEP reported the following levels of PrEP use: case D, 90% at the week 4 visit; case
E, 10% at the week 4 visit and 40% at the week 8 visit; case F, 100% at the week 4, 8, 13, and 26 visits and 90% at the week 39 visit; case G, 10% at the week
4 and 13 visits, 40% at the week 8 visit, 90% at the week 26 visit, and 100% at the week 39 visit (note that this visit occurred 35 calendar weeks after enrollment);
case H, 20% at the week 4 visit and 60% at the week 13 visit.
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not detected in any of the samples tested. In one case (case G), a low concentration of
FTC (0.87 ng/ml, consistent with 1 dose/week) was detected at the HIV seroconver-
sion visit using the quantitative TFV-FTC assay. In the last case (case H), both drugs were
detected by both assays at two study visits prior to seroconversion (TFV and FTC
concentrations of 52.2 and 59.8 ng/ml, respectively, at the first visit and 28.4 and 18.4
ng/ml at the second visit, consistent with daily dosing and 4 doses/week, respec-
tively). Self-reported data on PrEP adherence are provided in the Fig. 2 legend. Some
discrepancies were noted between self-reported data and data from ARV drug testing.
For example, the participant in case F reported 100% PrEP use at all visits but TFV and
FTC were not detected by either assay at any visit. This participant was diagnosed with
HIV infection at the study site at the week 52 visit and reported using PrEP until that
time; however, retrospective HIV testing at the HPTN Laboratory Center revealed that
the participant had acute HIV infection at the prior study visit (at week 39).
HIV drug resistance was assessed using an FDA-cleared HIV genotyping system
based on population sequencing (ViroSeq) and next-generation sequencing (NGS)
(Table 3). This testing was performed using samples collected at the first HIV-positive
visit for all cases except case F; in that case, resistance testing was performed using a
sample collected at the visit when HIV infection was diagnosed at the study site (week
52). Mutations associated with TFV and FTC resistance were not detected using the
ViroSeq system. The K65R mutation was detected at a low frequency (2.5%) in one case
using NGS; in that case (case G), a very low concentration of FTC was detected in plasma
at the time of HIV seroconversion, consistent with one dose of TDF-FTC in the prior
week (Fig. 2). The nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance
mutation K103N was detected in two cases using both methods. The low-frequency
protease inhibitor (PI) resistance mutation M46I was detected in one case using NGS
only. The polymorphic integrase strand transfer inhibitor (INSTI) resistance mutations
T97A and E157Q were detected in two cases using both methods. In one case, N155S
(reported as a rare nonpolymorphic mutation selected in vitro [24]) was detected using
NGS only.
DISCUSSION
Many methods used to monitor adherence to antiretroviral therapy (ART) and PrEP,
such as self-reporting, pill counting, and electronic monitoring, have limitations (12, 25,
26). When data are collected by self-report, some individuals may forget when they
TABLE 3 HIV drug resistance mutations detected using the ViroSeq HIV-1 genotyping system and next-generation sequencing
Case
Mutation (frequency of reads [%])a
Protease Reverse transcriptase Integrase
Resistance-associated
drugsbViroSeq NGS ViroSeq NGS ViroSeq NGS
A None None K103N K103N (99.12) None None EFV, NVP
B None None None None None N155S (2.3) EVG, RAL
C None None None None None None
D None None None None T97A,c E157Qc T97Ac (98.6),
E157Qc
(99.11)
EVG, RAL
E None M46I (2.7) None None None None ATV, LPV
F None None None None E157Qc E157Qc (98.8) EVG, RAL
G None None K103N K65R (2.5), K103N (99.0) None None TDF, DDI, ABC, D4T,
FTC, 3TC, EFV, NVP
H None None None None None Q146Ld (5.2)
aHIV drug resistance testing was performed using two methods, ViroSeq HIV-1 Genotyping System, v2.8 (Abbott Molecular, Des Plaines, IL) and NGS using the MiSeq
system (Illumina, San Diego, CA). The mutations detected in HIV protease, reverse transcriptase, and integrase are indicated. The frequency of NGS reads with each
mutation is shown in parentheses. Major resistance mutations are shown in bold, and drugs with reduced susceptibility are shown. Polymorphic mutations (e.g., L10V
and L71T in HIV protease) are not shown.
bEFV, efavirenz; NVP, nevirapine; EVG, elvitegravir; RAL, raltegravir; ATV, atazanavir; LPV, lopinavir; TDF, tenofovir disoproxil fumarate; DDI, didanosine; ABC, abacavir;
D4T, stavudine; FTC, emtriciabine; 3TC, lamivudine.
cAccessory mutation.
dQ146P is associated with reduced susceptibility to elvitegravir; Q146L is an unusual mutation.
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took the drugs, and others may choose to provide socially desirable answers (27). In a
clinical trial setting, enrollment criteria and other features of the trial design may
inadvertently encourage some participants not to disclose knowledge of their HIV
status or ARV drug use (19, 28). ARV drug testing provides an objective biomedical
measure of ARV drug use. This study evaluated the performance of a high-throughput,
qualitative, multidrug assay in evaluating exposure to TDF-FTC PrEP. Results obtained
with the multidrug assay were also compared to quantitative adherence assessments.
Comparison of results from the multidrug assay and a quantitative, gold-standard,
LC-MS/MS assay for TFV and FTC showed that the multidrug assay detected TFV
and FTC in all cases in which the drugs were present at concentrations above the 90%
sensitivity thresholds established for daily TDF-FTC use in a directly observed dosing
study (13). Because of its lower sensitivity, however, the multidrug assay may not detect
drugs with less than daily TDF-FTC dosing. Also, because the lower LOD of the
multidrug assay (20 ng/ml for TFV and FTC) is below the 90% sensitivity threshold
for daily adherence, it is possible that individuals who are taking TDF-FTC less often
than daily (in the 4-dose/week range) could be misclassified as adherent to a daily
regimen. The high level of agreement between the multidrug assay and the
quantitative LC-MS/MS assay observed in this report reflects the high level of
adherence to PrEP in the HPTN 073 cohort. Quantitative data are required to
determine the level of adherence to TDF-FTC PrEP, particularly for individuals with
less than daily dosing.
In addition to detecting TFV and FTC, the multidrug assay detects 18 other ARV
drugs in five drug classes. This allowed us to explore whether the men enrolled in HPTN
073 were using any other ARV drugs. In a previous study, we analyzed ARV drug use
among HIV-infected men in the HPTN 061 study (2009 to 2011), which enrolled 1,553
Black MSM in six cities in the United States, including the three sites in HPTN 073 (19,
21). At the time when HPTN 061 was performed, there were no ARV drugs approved for
PrEP for sexual HIV transmission. Many of the men in HPTN 061 who reported no
current or prior ARV drug use had ARV drugs detected in study samples (21). In most
cases, the drugs detected were consistent with ART regimens recommended at the
time of the study. Many of the men for whom drugs were detected did not demon-
strate viral suppression and many were using unusual combinations of drugs, which
likely contributed to the high frequency of drug resistance observed in that cohort (19).
Unusual patterns of ARV drug use were also detected among seroconverters in the
HPTN 061 cohort (19). In another study (HPTN 064 [2009 to 2010]), we found unusual
patterns of ARV drug use among HIV-uninfected women in the United States who were
at increased risk of HIV acquisition (20, 29). Those findings prompted analysis of ARV
drug use among HIV-uninfected men and seroconverters in HPTN 073, which began in
2013, after FDA approval of TDF-FTC for PrEP. In HPTN 073, the study drugs (TFV and
FTC) were the only drugs detected. The availability of an approved and proven
intervention for preventing HIV infection might have reduced the motivation of par-
ticipants in HPTN 073 to use other ARV drugs off-label. However, it is also possible that
we did not observe the use of other drugs among the Black MSM in HPTN 073 because
the number of participants was relatively small and because many ARV drugs have
short half-lives and would not be detected unless they were taken close to the time of
sample collection.
Another interesting finding in this report was the detection of TFV and FTC in
samples from 3 (1.4%) of 208 men at the time of study enrollment, which indicated that
these men did not disclose the use of PrEP to the study staff when they enrolled in the
study; disclosure of PrEP use within 60 days of enrollment would have excluded them
from participation in the study. This provides further support for the use of an objective
biomedical measure to assess ARV exposure in clinical studies. The actual frequency of
PrEP exposure at study entry might have been higher, since the multidrug assay has
relatively high cutoff values for TFV and FTC detection (20 ng/ml) and does not reliably
detect nondaily PrEP use.
In HPTN 061, HIV drug resistance mutations were detected in samples from 9
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(23.1%) of 39 newly infected Black MSM (seroconverters and men with recent HIV
infection) using the ViroSeq system (integrase genotyping and NGS were not per-
formed in that study) (19). In HPTN 073, resistance mutations were detected for 4
(50.0%) of the 8 seroconverters. Resistance to the study drugs (TDF and FTC) was
detected in only one case. K65R, which is associated with resistance to TDF, FTC, and
other nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), was detected in
one seroconverter sample that also contained the NNRTI resistance mutation K103N.
TDF was not detected in any of the samples from this participant, and FTC was detected
at a low level in only one sample, indicating infrequent PrEP use. We did not detect
resistance to TDF and FTC in samples from the six men for whom no study drugs were
detected at any study visit. In one case, study drugs were consistently detected in study
samples, indicating high levels of PrEP adherence; no major resistance mutations were
detected in the seroconversion sample from that case.
A limitation of both assays used in this study (the multidrug assay and the quanti-
tative TFV-FTC assay) is that the assays are subject to the “white coat” effect (i.e.,
detection of drugs in individuals who were not taking the drugs regularly but took the
drugs within 1 day before sample collection). Assays that detect TFV in hair or TFV
diphosphate in peripheral blood mononuclear cell (PBMC) or dried blood spot (DBS)
samples are less susceptible to this white coat effect but do not reflect very recent drug
dosing. However, the frequency of a white coat effect, as quantified by comparing data
from plasma assays with data from other sample types, was consistently very low in
several PrEP studies (C. W. Hendrix, unpublished data).
Quantitative drug assessments using LC-MS/MS methods represent the gold
standard for monitoring adherence to TDF-FTC PrEP. This report demonstrates that
the multidrug assay provides a complementary approach to quantitative assess-
ments of PrEP adherence by providing information about exposure to a daily
TDF-FTC regimen. It also provides new and reassuring data suggesting that the use
of other ARV drugs among HIV-uninfected and newly infected Black MSM in the
United States is infrequent. The multidrug assay is currently being modified to
include the newer INSTIs cabotegravir and elvitegravir, which will be useful in future
surveys of ARV drug use in different populations and settings (e.g., ART in HIV-infected
individuals, daily TDF-FTC PrEP, postexposure prophylaxis [PEP], and recreational ARV
drug use). The relatively low cost of the multidrug assay allows analysis of large sample
sets (20, 22), which may also be useful for surveillance of ARV drug use and larger
research studies.
MATERIALS AND METHODS
Clinical samples. Plasma samples were obtained from men enrolled in HPTN 073 (ClinicalTrials
registration no. NCT01808352). Eligibility criteria for HPTN 073 included high risk for HIV acquisition, no
prior HIV diagnosis, and no record of ARV drug use for PrEP or PEP in the 60 days prior to anticipated
enrollment. Study interventions included offering once-daily oral TDF-FTC (Truvada, a fixed-dose com-
bination tablet containing 300 mg TDF and 200 mg FTC) and client-centered care coordination, which
was provided to promote and to support PrEP use. The study enrolled 226 HIV-uninfected Black MSM;
79% of the men accepted PrEP. HIV testing was performed at the study sites. Additional testing was
performed retrospectively at the HPTN Laboratory Center (Johns Hopkins University, Baltimore, MD); this
included additional HIV testing for quality assurance and confirmation of HIV infection. Study participants
were followed for 12 months; 8 men acquired HIV infection during the study (5/178 who accepted PrEP
and 3/48 who did not accept PrEP).
ARV drug testing. (i) Multidrug assay. Plasma samples were tested for the presence of 20 ARV
drugs using a qualitative assay based on HRMS (18). The 20 drugs included 6 NRTIs (abacavir, FTC,
lamivudine, stavudine, TFV, and zidovudine), 3 NNRTIs (efavirenz, nevirapine, and rilpivirine), 9 PIs
(amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir), a
CCR5 receptor antagonist (maraviroc), and an INSTI (raltegravir). Briefly, 100 l plasma was prepared with
300 l methanol plus 0.025% formic acid, containing FTC 13C 15N2 (internal standard) at 20 ng/ml,
in individual wells of a Phenomenex Impact protein precipitation plate. ARV drugs were detected by
high-performance liquid chromatography (HPLC) coupled with high-resolution accurate mass
(HRAM) mass spectrometry (MS) (QExactive-Orbitrap; Thermo Scientific, San Jose, CA). The mobile
phase system was as follows: solvent A, water plus 10 mM ammonium formate plus 0.05% formic
acid; solvent B, methanol plus 0.05% formic acid. After the samples were loaded onto a Thermo
Synchronis C18 guard column (10 by 4.0 mm; particle size, 5 m), elution occurred during a 120-s
ramp to 100% organic mobile phase. Full-scan data-dependent MS2 analysis was performed with a
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resolution of 17,500 at m/z 200 for both full MS and MS2 scans. An effective analysis time of 2.0
min/sample was achieved by multiplexing with a 4-channel chromatography system. Controls were
included with each batch or plate (2, 20, 200, and 2,000 ng/ml for each drug); if the results for the
controls on each plate did not match within a predetermined tolerance, then the plate was
reanalyzed. Abacavir, maraviroc, nelfinavir, nevirapine, raltegravir, and rilpivirine were consistently
detected at or above 2 ng/ml; the remaining 14 drugs, including TFV and FTC, were consistently
detected at or above 20 ng/ml.
(ii) Quantitative TFV-FTC assay. Plasma samples were also analyzed using an assay based on
LC-MS/MS that quantified TFV and FTC (14). Briefly, following the addition of isotopically labeled
internal standards and sample extraction via protein precipitation, samples were subjected to
LC-MS/MS analysis. Chromatographic separation was performed using an Agilent Zorbax Eclipse Plus
C18 column (2.1 by 50 mm; particle size, 3.5 m), with detection using an API4000 mass analyzer
(SCIEX, Foster City, CA) operated in positive ionization and selective reaction monitoring (SRM)
modes. The lower limits of quantification were 0.31 ng/ml for both drugs. The assay was validated
in accordance with U.S. FDA guidelines and was externally reviewed by the Clinical Pharmacology
Quality Assurance (CPQA) program sponsored by the Division of AIDS (30). Testing was performed
for seroconverters at all study visits; testing was limited to end-of-study samples for uninfected men,
due to cost considerations.
HIV drug resistance testing. HIV genotyping was performed using the ViroSeq HIV-1 v2.8 geno-
typing system (Abbott Molecular, Des Plaines, IL). Viral RNA extracted from plasma samples with the
ViroSeq HIV-1 genotyping system was used for next-generation sequencing. Next-generation sequencing
was performed using methods adapted from a previous study (31). The MiSeq system (Illumina, San
Diego, CA) was used to generate paired-end reads (2 by 250 bp). The reads were then trimmed for quality
(limit threshold, 0.05) and ambiguity (2-nucleotide maximum) by using CLC Genomics Workbench v9.5
software (Qiagen, Aarhus, Denmark). After the PCR primers were removed, reads were aligned to a
reference sequence (HXB2 [GenBank accession no. NC_001802]) with the following alignment settings:
mismatch, 2; insertion, 3; deletion, 3; length fraction, 0.7; similarity fraction, 0.8. The low-frequency variant
detection tool from the CLC Genomics Workbench software was used to identify resistance mutations
(frequency cutoff value: 2%; minimum number of variants: 2,000 reads). The Stanford University HIV drug
resistance database (https://hivdb.stanford.edu/hivdb/by-mutations) was used to generate HIV drug
resistance reports.
Statistical methods. Sensitivity, specificity, and accuracy were calculated to characterize the per-
formance of the multidrug assay, using the quantitative TFV-FTC assay as the gold standard.
Ethics approval. All study participants provided informed consent for participation in the HPTN 073
study. The study was approved by the participating academic institutions and ethics committees for each
study site.
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